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ABSTRACT
Sorafenib is the first-line drug used for patients with advanced hepatocellular 
carcinoma (HCC). However, acquired sorafenib resistance in cancer patients limits its 
efficacy. Here, we performed the first genome-wide CRISPR/Cas9-based screening on 
sorafenib-treated HCC cells to identify essential genes for non-mutational mechanisms 
related to acquired sorafenib resistance and/or sensitivity in HCC cells. KEAP1 was 
identified as the top candidate gene by Model-based Analysis of Genome-wide 
CRISPR/Cas9 Knockout (MAGeCK). KEAP1 disrupted HCC cells were less sensitive 
than wild-type cells in short- and long-term sorafenib treatments. Compared to wild-
type cells, KEAP1-disrupted cells showed lower basal and sorafenib-induced reactive 
oxygen species (ROS) levels and were more resistant to oxidative stress-induced cell 
death. The absence of KEAP1 led to increased activity of Nrf2, a key transcription 
factor controlling antioxidant responses, as further evidenced by increased expression 
of Nrf2-controlled genes including NQO1, GPX2 and TXNRD1, which were positively 
associated with chemoresistance. In addition, KEAP1 disruption counteracted the 
reduction of cell viability and the elevation of ROS caused by lenvatinib, a drug that 
recently showed clinical efficacy as a first-line treatment for unresectable HCC. Finally, 
Keap1 disruption also increased the resistance of cells to regorafenib, a recently 
approved drug to treat HCC as a second line therapy. Taken together, our data 
indicate that deregulation of the KEAP1/Nrf2 pathway following KEAP1 inactivation 
contributes to sorafenib, lenvatinib, and regorafenib resistance in human HCC cells 
through up-regulation of Nrf2 downstream genes and decreased ROS levels.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the most 
common type of primary liver cancer and the second most 
frequent cause of cancer death [1]. The only treatment 
available for advanced HCC is molecular targeted therapy 
using sorafenib (Nexavar®) or, since very recently, 
lenvatinib (Lenvima®). These drugs mainly act on serine-
threonine kinases such as Raf-1 and on receptor tyrosine 
kinases such as vascular endothelial growth factor receptor 
(VEGFR) and platelet-derived growth factor receptor 
β (PDGFR-β) [2, 3], inhibiting angiogenesis, proliferation 
and tumor growth. Even though the median overall 
survival time is slightly higher in drug-treated patients 
compared to placebo [4, 5], the final prognosis remains 
dismal. The resistance that HCC acquires to these drugs 
is likely favored by genetic instability and heterogeneity 
leading to molecular and signaling alterations. For 
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example,  activation  of  the  PI3K/Akt/mTOR  pathway, 
inhibition  of  the  JAK/STAT  pathway,  and  increased 
autophagy have been associated with sorafenib resistance 
[6]. However, the mechanisms of sorafenib and lenvatinib 
resistance are still incompletely understood. Their 
elucidation may help to uncover molecular biomarkers to 
predict sensitivity to HCC treatment, as well as to identify 
new treatment strategies to overcome drug resistance. 
Recently, the CRISPR/Cas9 genome editing technology 
has been efficiently used to screen for genes involved in 
resistance to drugs. However, most studies are focused on 
parental cancer cells for initial drug response [7, 8]. Here, 
we established a sorafenib resistant cell line and performed 
a  CRISPR/Cas9  screen  to  identify  potential  genes 
modulating acquired sorafenib resistance. This screen 
identified KEAP1 as a susceptibility gene to sorafenib.
RESULTS
A genome-wide CRISPR/Cas9 screening identifies 
KEAP1 as a gene involved in sorafenib sensitivity











were therefore used for the screening.
A CRISPR/Cas9-based genome-wide screening was 
used to identify genes in HUH-7 SR cells that conferred 
resistance to sorafenib [10], using the strategy shown in 
Figure 1B. Cells expressing the lentiviral sgRNA library 
were grown for 12 doubling times in  the absence or  in 
the presence of sorafenib. Cells expressing the library 
but  not  subjected  to  12  doublings  served  as  a  control 
group. First, we looked for sgRNAs depleted in sorafenib-
treated HUH-7 SR cells, because these could target genes 
required for the maintenance of sorafenib resistance. 
The rationale is that if a gene is required for sorafenib 
resistance,  cells  expressing  the  sgRNAs  targeting  this 
gene would have a survival or growth disadvantage in the 
presence of the drug. However, no significantly under-
represented sgRNAs were identified and thus our screen 




cells treated with sorafenib (Figure 1C). The 10 enriched 
genes with the highest enrichment of their corresponding 
sgRNAs  following  sorafenib  treatment  are  listed  in 
Supplementary Table 1. Among  them, KEAP1 was  the 
only gene with a FDR (false discovery rate) lower than 
0.05.  Increased  expression  of  the  KEAP1-targeting 
sgRNAs  was  not  caused  by  a  gene  drift  phenomenon 
that could occur when a cell population is cultured for 
long time periods, because there were no differences in 
the  abundance  of  KEAP1-targeting  sgRNAs  between 
untreated cells analyzed before and after the 12 doubling 
time period (Figure 1D). As there seems to be a selective 




to a sorafenib-sensitivity gene. The next set of experiments 
were designed to test this hypothesis. As KEAP1 does not 
contribute  to  the  initial  resistance  of HUH-7  SR  cells, 
these experiments were performed in the parental cells.
KEAP1 invalidation decreases sorafenib 
sensitivity in HUH-7 cells
To  validate  the  role  of  KEAP1  in  sorafenib 
susceptibility and to further investigate the role of KEAP1 
in  cells  treated  with  the  drug,  we  generated  KEAP1 
knockout HUH-7 cells. Using two different sgRNAs from 
the sgRNA library (Supplementary Figure 1A), we isolated 
two independent clones carrying different disrupting 
mutations in the KEAP1 alleles (Supplementary Figure 




Figure  1A).  KEAP1  functions  as  a  repressor  of  Nrf2 








and the subsequent activation of its downstream target 





(Figure  2A  and  Supplementary  Figure  3A),  KEAP1-
disrupted cells showed higher viability in the presence 





to form colonies in the presence of sorafenib was also 
higher  in  cells  lacking KEAP1  (Figure  2E–2F). These 
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Figure 1: Single guide RNAs targeting KEAP1 are enriched in sorafenib-treated HUH-7 cells. (A) Sorafenib-resistant cells 
(SR) were derived from wild-type HUH-7 cells (WT) by three month exposure to 5 µM sorafenib. The WT and SR cells were treated with 
the indicated concentrations of sorafenib for 72 hours and viability was assessed by the MTS assay. Symbols are off set for clarity. The 















Previous  studies  have  shown  that  apart  from 
targeting tyrosine and serine kinases, one possible anti-
cancer mechanism of sorafenib in HCC is the induction 
of oxidative stress [14]. To investigate the oxidative stress 
levels in wild-type and KEAP1-disrupted cells, ROS levels 
were  examined  by  H2DCFDA  assay.  This  confirmed 





the KEAP1  disrupted  cells  (Figure  3C). This  indicates 
that the absence of KEAP1 activity in cells allows them 
to  mitigate  sorafenib-induced  ROS  accumulation.  To 
further validate the role of the cellular antioxidant capacity 






menadione [15]. These inducers decreased cell viability 
in wild-type  cells more  than  in KEAP1-disrupted  cells 
(Figure 3D and Supplementary Figure 3D), confirming 
that KEAP1-disrupted cells  are more  resistant  to drug-
induced oxidative stress.
The Nrf2 pathway is functional in HUH-7 cells
KEAP1 is a Cul3-based E3 ligase (Supplementary 
Figure 1A) that targets the Nrf2 transcription factor for 
degradation  [16]. Nrf2  controls  the  expression  of  anti-
oxidative  genes,  such  as  NQO1,  through  binding  to 
antioxidant response elements (AREs) in their regulatory 
sequences, thereby increasing their basal and oxidative 
Figure 2: KEAP1 disruption decreases the sensitivity to sorafenib. (A) Cell proliferation of wild-type and KEAP1-disrupted 





The results were derived from three independent experiments. (E) Clonogenic cell survival assay. Cells were treated with sorafenib at the 
indicated concentrations for two days. Then, 8,000 cells were seeded in new six well plates. Eight days later, cells were washed with PBS 
and stained with Crystal violet. (F) The quantitation of clonogenic growth was done by measuring the crystal violet content in the plates. 




is  responsible  for  the  binding  to  Nrf2.  To  investigate 
if  KEAP1  disruption  activates  the  Nrf2  pathway  in 
our  experimental  setting,  we  first  measured  Nrf2 
transcriptional activity by transfecting cells with a plasmid 
bearing the NQO1 promoter ARE sequence upstream of 




activating  compound  [19].  As  expected,  sulforaphane 
increased Nrf2 transcriptional activity in control HUH-7 
cells but was unable to further augment the already high 
Nrf2 activity in KEAP1-disrupted cells (Figure 4A). The 
ability  of  the  KEAP1-disrupted  cells  to  repress  basal 
Nrf2  activity  was  restored  by  forced  over-expression 




Nrf2  has  a  wide  array  of  target  genes,  which  are 
associated with several processes involved in cellular 
homeostasis maintenance. Therefore, the expression alterations 
of  downstream  target  genes  including NQO1, GPX2,  and 





Figure 3: Sorafenib-induced ROS accumulation is reduced in KEAP1 disrupted cells. (A) Wild-type cells were exposed to 
different concentrations of sorafenib for 24 hours followed by ROS level measurement. The results were derived from four independent 
experiments (with two technical replicates each). (B) Basal ROS levels in wild-type cells and KEAP1 disrupted cells. The results were 
derived from two independent experiments (1 in duplicate and 1 in triplicate). (C) ROS levels in response to a 24 hour sorafenib stimulation 





 or menadione for 7 hours at the indicated concentrations 
and cell viability was assessed using the MTS assay. Results correspond to the mean ± standard error of the mean. The results were derived 
from four independent experiments.
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genes, including NQO1 [20], GPX2 [21], and TXNRD1 [22], 
is strongly associated with poor prognosis in HCC patients. 
These results further suggested that depletion of KEAP1 might 
contribute to HCC progression by increasing the transcription 
levels of Nrf2 target genes.
The effects of KEAP1 disruption on lenvatinib 
and regorafenib sensitivity
Lastly, we tested whether KEAP1 disruption also 
decreased the sensitivity of HCC cells to lenvatinib, 
a drug that was shown recently to be as efficacious as 
sorafenib to treat HCC [5]. Like sorafenib, lenvatinib is 
a broad tyrosine kinase inhibitor, whose targets include 
VEGF  receptors  and  FGF  receptors  [3].  To  test  the 
effects of lenvatinib, cells were treated with different 
concentrations of the drug for 48 hours. Figure 5A shows 
that KEAP1 disruption inhibited lenvatinib-induced drop 




lenvatinib  susceptibility  gene.  Additionally,  KEAP1-
disrupted cells were also less sensitive to regorafenib 
(Stivarga®) (Supplementary Figure 5), a drug approved as 
a second-line therapy for patients progressing during or 
after sorafenib therapy [23].
DISCUSSION
Previous  studies  have  shown  that  sorafenib  has 
a beneficial therapeutic effect on the treatment of HCC 
patients [4]. However, only a small fraction of HCC 
patients are sensitive to sorafenib and sorafenib resistance 
develops very often during treatment, limiting its utility 
[24]. Therefore,  it  is of  importance  to  further elucidate 
the mechanisms related to sorafenib action and resistance. 
In our study, we demonstrated  that  the KEAP1 gene  is 
Figure 4: Defective regulation of Nrf2 target genes in KEAP1-disrupted cells. (A) ARE-driven  luciferase  activity  was 
measured in wild-type and KEAP1-disrupted cells. Sulphoraphane (5 µM) was used as a positive Nrf2-inducing control. The results were 




involved in acquired sorafenib resistance using a genome-
wide  CRISPR/Cas9  screening.  In  HCC  cells  lacking 
KEAP1,  basal  and  sorafenib-induced ROS  levels were 
impaired. Furthermore, KEAP1 disruption led to increased 
Nrf2 activity and expression of Nrf2-driven genes. Our 
results  indicate  that  KEAP1  disruption  contributes 






tumor cell death is an important therapeutic strategy in 
cancer  treatment. Here, we  confirmed  that ROS  levels 
were increased by sorafenib in wild-type HUH-7 cells, but 
not in KEAP1-disrupted cells. At the same time, KEAP1-
disrupted cells were more resistant to oxidative stress-
induced proliferation impairment and death. This suggests 
that loss of KEAP1 causes sorafenib resistance through 
suppression of cellular oxidative stress.
The KEAP1/Nrf2  pathway  is  a  major  regulator  of 
cellular  responses  to  oxidative  stress.  Western  blot  and 
luciferase  assay  demonstrated  that  Nrf2  transcriptional 
activity was induced in KEAP1 disrupted HUH-7 cells. A 
number  of ARE-containing  genes  are  regulated  by Nrf2, 
which can be divided into 5 groups: antioxidant enzymes, 
NADPH-generating enzymes, metal-binding proteins, drug-













One  limitation  of  this  study  is  that  only  one 
hepatocarcinoma cell line (HUH-7 cells) was investigated. 
Further work on additional HCC cell lines might therefore 
be required to extent the findings of the present paper. In 
this context however, it is worth mentioning that a recent 
study has indeed demonstrated that sorafenib resistance 





a sorafenib-sensitivity gene in both resistant and wild-
type HCC cells and further extended these findings to 
the recently approved anti-HCC drugs, lenvatinib and 
regorafenib.
An  interesting  effect  was  sometimes  observed 
(see  Figure  1A  for  example):  in  response  to  very  low 
doses of sorafenib or  lenvatinib HUH-7 cells  tended to 
display increased viability (or growth or mitochondrial 
metabolism) compared to non-treated cells. This can be 
related to earlier work showing that low non-lethal stresses 
can  paradoxically  favor  cell  survival.  One  proposed 
mechanism for such responses is that low stresses induce 
mild caspase-3/7 activity, leading to partial cleavage of 




Figure 5: KEAP1 disruption confers resistance to lenvatinib. Cells were treated with the indicated concentrations of lenvatinib 
for 48 hours. (A) Cell viability was assessed using the MTS assay. The results were derived from three independent experiments. (B) ROS 
levels were measured as indicated in the Materials and Methods section. The results were derived from seven independent experiments.
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loss mediates sorafenib, lenvatinib, and ragorafenib 
resistance, we suggest that patients with HCC that 
are resistant to first-line treatment with sorafenib, if 
mediated by KEAP1 loss-of-function, will not respond 
to second-line treatment with lenvatinib or ragorafenib 
(and  vice-versa).  KEAP1/Nrf2  pathway  inactivation 
(through  KEAP1  or  Nrf2 mutations  for  example)  can 
be a poor prognostic factor for HCC treatment and 
help clinicians predict the characteristics of specific 
cancers. Clinical translational studies are warranted to 
test these hypotheses, which are critical to guide patient 
management and especially to avoid treatment failures, 
systemic side-effects, delays and costs from ineffective 
drug choices.
Secondly, the requirement of KEAP1/Nrf2 pathway 
deregulation for sorafenib resistance in both parental 
and acquired resistant HCC cells provides a potential 
intervention  target  for  future  therapies. Aberrant  Nrf2 
activation occurs not only in HCC cancer but also in 
many  other  types  of  cancer  [34,  35].  Sustained  Nrf2 
activation promotes the survival and proliferation of 




the  importance  of  the  KEAP1/Nrf2  pathway  in  both 
acquired and primary sorafenib resistance, suggests that 
Nrf2 inhibitor could be beneficial not only in the initial 
treatment stages targeting primary tumors, but also in 





















 solution and menadione 
were purchased from Sigma (ref. no. D6883, H1009, and 
M2518).  Lipofectamine  2000  reagent  and  sulforaphane 
were obtained from Invitrogen (ref. no. 11668019) and Enzo 
Life Science (ref. no. ALX-350-230-M010), respectively. 




MTS/PMS cell metabolic activity assay
This  assay  records  the  NAD(P)H-dependent 
cellular oxidoreductase enzyme activity, a proxy for 
cell  viability.  Cells  were  plated  in  96-well  plates  and 





































g to pellet the cells. The supernatant was filtered through 
a 0.45 μm HV/PVDF (Millipore, ref. no. SE1M003M00) 
and concentrated 100x by ultracentrifugation at 70,000 g 
for 2 hours at 4°C. Virus pellet was resuspended in ice-
cold PBS, aliquoted and stored at –80°C.
The  Cas9  endonuclease  was  stably  expressed  in 








Twenty-four hours later, each well was split into duplicate 
wells and one well received 10 μg/ml puromycin for 3 days. 
Cell viability was determined by trypan blue exclusion. The 
minimal volume of viruses leading to ~100% survival was 
considered as the conditions giving a MOI of 1. For the 
CRISPR/Cas9 screen a MOI of 0.3 was chosen (to insure 














just after the puromycin selection (hence not submitted to 
the 12 doublings).
A  first  PCR  was  performed  to  amplify  the 
lentiCRISPR  sgRNA  region  with  primers  F1  and  R1 
(Table 1). A second PCR was performed to attach Illumina 
adaptors  and  barcodes  to  samples.  Five  μl  of  the  first 
PCR  product  were  used.  Primers  for  the  second  PCR 
included both a variable length sequence to increase library 
complexity and a 6 bp barcode for multiplexing of different 
biological samples (F2a-R2_iA_12, Table 1). Both PCRs 
were  performed  in  100 μl with  the Herculase  II  Fusion 
DNA Polymerase  (Agilent,  ref. no. 600675). Amplicons 
were gel extracted, quantified, mixed and sequenced on 
a MiSeq  instrument  (Illumina). Raw FASTQ  files were 
demultiplexed and processed to contain only unique sgRNA 
sequences.  The  number  of  reads  of  each  sgRNA  was 
normalized as described [7]. The MAGeCK algorithm [38] 


























Seventy  thousand  wild-type  HUH-7  cells  and 
KEAP1-disrupted HUH-7  cells were  separately  seeded 
in  60  mm  dish  and  treated  with  5  µM  sorafenib  for  
12 days. Medium was changed every three or four days. 
Cell number was counted using a hemocytometer.
Measurement of cell death using propidium 
iodide (PI)
Eighty  thousand  wild-type  HUH-7  cells  and 
KEAP1-disrupted HUH-7 cells were separately seeded in 
six well plates and treated as indicated in the figures. All 
cells including floating cells in the medium were collected 
and  suspended  in  500  µl  PBS  solution  containing  PI  
(8 µg/ml). Cell death was measured by flow cytometry 





Reactive oxygen species (ROS) measurement
H2DCFDA was used to detect ROS generation. Cells 









was  determined  by  the Bradford  technique. ROS  levels 
were normalized against the protein content (fluorescence 
[arbitrary units] divided by microgram of protein).
Crystal violet assay
Cells  in  6-well  plates  or  35 mm Petri  dishes were 
washed once with PBS, air-dried for 10 minutes, and fixed 
with absolute ethanol for 10 more minutes. Cells then were 
stained with 0.05% crystal violet (in water/0.5% ethanol) for 
30 minutes. The plates were gently washed with water twice 
and air-dried for 10 minutes. For quantitation of this staining, 





density recordings for a given sample were averaged.
Antioxidant response element (ARE) luciferase 
reporter assay
Cells (100,000 in 500 μl) were seeded in 24-well 
plates. The following day, cells were transfected with 
a luciferase reporter plasmid (#998) driven by an ARE 
sequence  from  the NAD(P)H  quinone  dehydrogenase 
1  (NQO1)  promoter  [40]  using  Lipofectamine  2000 
for  48  hours.  The  pEGFP  plasmid  (#6)  coding  for 
green fluorescent protein was co-transfected to assess 
transfection efficiency. After treatment with or without 
5  µM  sulphoraphane  for  24  hours,  GFP  fluorescence 
was measured  using  a Cytation  3  cell  imaging multi-
mode reader with an excitation wavelength of 480 nm 
and  an  emission  wavelength  of  520  nm.  To  measure 
the luciferase reporter activity, a luciferase reporter 
assay (Promega, UK) was performed according  to  the 
manufacturer’s  protocol.  Luciferase  activities  were 
normalized  to  GFP  fluorescence.  Relative  luciferase 









amplicon. Relative expression of genes is expressed as 
fold change over control.
Statistics and data presentation
Comparisons between multiple groups were 
performed using one-way ANOVA followed by Sidak’s 
multiple  comparisons  test  using  GraphPad  Prism. 
Comparisons between two groups were performed using 
Student’s  t-test or Sidak’s multiple comparisons  test  in 
GraphPad Prism. Horizontal bars in the figure correspond 
to the mean. When normalization is shown in figures, the 
individual replicates of a given experiment (including 
those of the control group) are normalized against 
the average value of the control group for this given 
experiment.
Author contributions









Constantin for their dedicated technical support during 
this project. CW was supported by grants from the Swiss 
National  Science  Foundation  (no.  CRSII3_154420, 
31003A_160181/1,  IZCSZ0-174639,  respectively). NC 
was supported by a grant from the Swiss National Science 
Foundation  (MD-PhD  fellowship  n°158116). GPS was 
supported  by  grants  from  the  Swiss  National  Science 




The authors declare no potential conflicts of interest.
REFERENCES
  1.  Kim  JU,  Shariff MI,  Crossey MM,  Gomez-Romero M, 
Holmes E, Cox IJ, Fye HK, Njie R, Taylor-Robinson SD. 









versus placebo in radioiodine-refractory thyroid cancer. N 











treatment of patients with unresectable hepatocellular 







  7.  Shalem O,  Sanjana NE, Hartenian E,  Shi X,  Scott DA, 
Mikkelson T, Heckl D, Ebert BL, Root DE, Doench JG, 
Zhang F. Genome-scale CRISPR-Cas9 knockout screening 

















screening.  Nat  Protoc.  2017;  12:828–63.  https://doi.
org/10.1038/nprot.2017.016. [PubMed]
11.  Nguyen  T,  Nioi  P,  Pickett  CB.  The  Nrf2-antioxidant 










14.  Coriat  R,  Nicco  C,  Chéreau  C,  Mir  O,  Alexandre  J, 
Ropert S, Weill B, Chaussade S, Goldwasser F, Batteux 
F. Sorafenib-induced hepatocellular carcinoma cell death 
depends on reactive oxygen species production in vitro and 
in vivo. Mol Cancer Ther. 2012; 11:2284–93. https://doi.
org/10.1158/1535-7163.MCT-12-0093. [PubMed]
15.  Loor  G,  Kondapalli  J,  Schriewer  JM,  Chandel  NS, 
Vanden  Hoek  TL,  Schumacker  PT.  Menadione  triggers 
cell death through ROS-dependent mechanisms involving 
PARP activation without requiring apoptosis. Free Radic 





17.  Kaspar  JW,  Niture  SK,  Jaiswal  AK.  Nrf2:INrf2 
(Keap1)  signaling  in  oxidative  stress.  Free  Radic  Biol 
Med.  2009;  47:1304–09.  https://doi.org/10.1016/j.
freeradbiomed.2009.07.035. [PubMed]
18.  Sykiotis  GP,  Bohmann  D.  Stress-activated  cap’n’collar 
transcription factors in aging and human disease. Sci Signal. 









L.  Prognostic  implication  of  NQO1  overexpression  in 




indicates poor prognosis in patients with hepatocellular 
carcinoma.  Tumour  Biol.  2017;  39:1010428317700410. 
https://doi.org/10.1177/1010428317700410. [PubMed]






Carcinoma.  Drugs.  2018;  78:951–58.  https://doi.
org/10.1007/s40265-018-0932-4. [PubMed]
24.  Zhai B, Sun XY. Mechanisms of resistance to sorafenib and 
















transporter  SLC7A11  in  cancer  chemosensitivity  and 
chemoresistance. Cancer Res. 2005; 65:7446–54. https://
doi.org/10.1158/0008-5472.CAN-04-4267. [PubMed]
29.  Eichenmüller  M,  Trippel  F,  Kreuder  M,  Beck  A, 
Schwarzmayr  T,  Häberle  B,  Cairo  S,  Leuschner  I,  von 
Schweinitz  D,  Strom  TM,  Kappler  R.  The  genomic 






mutational landscape of hepatocellular carcinoma genomes. 




F,  Clément  B,  Balabaud  C,  Chevet  E,  et  al.  Integrated 
analysis of somatic mutations and focal copy-number 
changes identifies key genes and pathways in hepatocellular 
carcinoma.  Nat  Genet.  2012;  44:694–98.  https://doi.
org/10.1038/ng.2256. [PubMed]
32.  Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, Tang D. 
Activation  of  the  p62-Keap1-NRF2  pathway  protects 
against ferroptosis in hepatocellular carcinoma cells. 
Hepatology.  2016;  63:173–84.  https://doi.org/10.1002/
hep.28251. [PubMed]
33.  Yang JY, Michod D, Walicki J, Murphy BM, Kasibhatla 
S, Martin  SJ, Widmann C.  Partial  cleavage  of  RasGAP 














36.  Ngo  HK,  Kim  DH,  Cha  YN,  Na  HK,  Surh  YJ.  Nrf2 
Mutagenic Activation Drives Hepatocarcinogenesis. Cancer 
Res.  2017;  77:4797–808.  https://doi.org/10.1158/0008-
5472.CAN-16-3538. [PubMed]
37.  Tsuchida  K,  Tsujita  T,  Hayashi  M,  Ojima  A,  Keleku-
Lukwete  N,  Katsuoka  F,  Otsuki A,  Kikuchi  H,  Oshima 
Y, Suzuki M, Yamamoto M. Halofuginone enhances  the 
chemo-sensitivity  of  cancer  cells  by  suppressing  NRF2 












 anti-cancer peptide can kill in a 
caspase-, apoptosis-, and necroptosis-independent manner. 
Oncotarget.  2016;  7:64342–59.  https://doi.org/10.18632/
oncotarget.11841. [PubMed]
40.  Favreau  LV,  Pickett  CB.  The  rat  quinone  reductase 
antioxidant  response  element.  Identification  of  the 
nucleotide sequence required for basal and inducible 
activity and detection of antioxidant response element-
Oncotarget7070www.oncotarget.com
binding proteins in hepatoma and non-hepatoma cell lines. 
J Biol Chem. 1995; 270:24468–74. https://doi.org/10.1074/
jbc.270.41.24468. [PubMed]
41.  Gerber DE. Targeted therapies: a new generation of cancer 
treatments. Am Fam Physician. 2008; 77:311–19. [PubMed]
42.  Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens 
in human cells using the CRISPR-Cas9 system. Science. 
2014; 343:80–84. https://doi.org/10.1126/science.1246981. 
[PubMed]
